On Jan 25, 2024, new data comparing subcutaneous (SC) versus intravenous (IV) nivolumab in pre-treated advanced/metastatic ccRCC was unveiled at ASCO_GU 2024.
Teva Pharmaceuticals has released encouraging initial results concerning the safety, patient tolerance, and pharmacokinetic profile of its investigational product known as anti-TL1A (TEV-’574).
Lidocaine,the first amino amide–type local anesthetic,as opposed to the amino ester-type local anesthetics that were used before it, was originally called "xylocaine" .
NextPoint Therapeutics Reveals Initiation of Early-Stage Clinical Study with First Subject Receiving NPX887 for Solid Tumors Containing HHLA2, an Innovative Treatment Aiming to Revitalize Worn-Out T and NK Cells.
argenx has reported that the FDA has granted priority review status for their updated biologics application for VYVGART Hytrulo, aimed at treating chronic inflammatory demyelinating polyneuropathy.
Philogen Announces Preliminary Results from Phase III FIBROSARC Study Evaluating Onfekafusp alfa (L19TNF) in Initial Treatment of Advanced or Metastatic Soft Tissue Sarcoma.
Innovent Reveals Key Goal Achieved in Phase 3 Study (RESTORE-1) of IBI311 (IGF-1R-Targeting Agent) for Thyroid Eye Condition, Intends to File for Approval with NMPA.